Department of Medicine, University of Cambridge, Cambridge Institute for Medical Research, Wellcome Trust/MRC Building, Cambridge, CB2 0XY, UK.
Expert Rev Clin Immunol. 2011 Mar;7(2):243-52. doi: 10.1586/eci.10.95.
α(1)-antitrypsin deficiency is an autosomal recessive disorder that results from point mutations in the SERPINA1 gene. The Z mutation (Glu342Lys) accounts for the majority of cases of severe α(1)-antitrypsin deficiency. It causes the protein to misfold into ordered polymers that accumulate within the endoplasmic reticulum of hepatocytes. It is these polymers that form the periodic acid Schiff positive inclusions that are characteristic of this condition. These inclusions are associated with neonatal hepatitis, cirrhosis and hepatocellular carcinoma. The lack of circulating α(1)-antitrypsin exposes the lungs to uncontrolled proteolytic attack and so can predispose the Z α(1)-antitrypsin homozygote to early-onset emphysema. α(1)-antitrypsin polymers can also form in extracellular tissues where they activate and sustain inflammatory cascades. This may provide an explanation for both progressive emphysema in individuals who receive adequate replacement therapy and the selective advantage associated with α(1)-antitrypsin deficiency. Therapeutic strategies are now being developed to block the aberrant conformational transitions of mutant α(1)-antitrypsin and so treat the associated disease.
α(1)-抗胰蛋白酶缺乏症是一种常染色体隐性遗传疾病,由 SERPINA1 基因的点突变引起。Z 突变(Glu342Lys)占严重 α(1)-抗胰蛋白酶缺乏症的大多数病例。它导致蛋白质错误折叠成有序的聚合物,在肝细胞的内质网中积累。正是这些聚合物形成了 PAS 阳性内含物,这是这种情况的特征。这些内含物与新生儿肝炎、肝硬化和肝细胞癌有关。缺乏循环中的 α(1)-抗胰蛋白酶会使肺部暴露于不受控制的蛋白水解攻击之下,因此可能使 Z α(1)-抗胰蛋白酶纯合子易患早发性肺气肿。α(1)-抗胰蛋白酶聚合物也可以在细胞外组织中形成,在那里它们激活并维持炎症级联反应。这可能解释了为什么在接受充分替代治疗的个体中会出现进行性肺气肿,以及与 α(1)-抗胰蛋白酶缺乏相关的选择性优势。目前正在开发治疗策略来阻断突变型 α(1)-抗胰蛋白酶的异常构象转变,从而治疗相关疾病。